{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:05:55Z","timestamp":1780373155492,"version":"3.54.1"},"reference-count":32,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,5,13]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate the role of topical cyclosporine A 1% (CsA) as an adjuvant therapy in patients with acute Stevens-Johnson syndrome (SJS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a randomised controlled trial in which 44 patients (88 eyes) with acute SJS, presenting within 3 months from the onset of the disease, were enrolled and randomised. Group A (n=44 eyes) patients received treatment with topical CsA 1% along with standard therapy consisting of topical corticosteroids, antibiotics and lubricants. Group B (n=44 eyes) patients received topical saline drops in combination with standard therapy. Various ocular surface parameters were assessed at baseline and the 6-month follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age of patients (years) was 23.9\u00b115.1 in the CsA group and 26.0\u00b118.7 in the control group (p=0.6840). The mean time from disease onset to presentation (days) was 17.0\u00b114.0\u2009and 12.9\u00b111.3 in CsA and control groups, respectively (p=0.1568). At presentation, the mean grades of severity scores of various parameters were comparable. At 6 months, both groups showed a significant improvement in the mean severity grades of conjunctival hyperaemia (A, p=0.001; B, p=0.0001), mucocutaneous junction involvement (A, p=0.001; B, p=0.0001) and meibomian gland involvement (A, p=0.0471; B, p=0.006). Compared with baseline, the grades of corneal keratinisation (baseline, 0.48\u00b10.7; 6 months, 1.02\u00b10.8; p=0.0015) and neovascularisation (baseline, 1.07\u00b11.2; 6 months, 1.57\u00b11.0; p=0.0412) worsened after 6 months of CsA therapy. Intergroup comparison of grades of various parameters however did not reveal any significant difference at 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Adjuvant treatment with topical CsA is not superior to standard therapy, in cases of acute SJS.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2023-324901","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T17:20:25Z","timestamp":1716830425000},"page":"10-14","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of adjuvant role of topical cyclosporine 1% in acute Stevens-Johnson syndrome: a randomised control trial"],"prefix":"10.1136","volume":"109","clinical-trial-number":[{"clinical-trial-number":"isrctn11036223","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7542","authenticated-orcid":false,"given":"Namrata","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-0173","authenticated-orcid":false,"given":"Ritu","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshini","family":"K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamna","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal K","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NR","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumurthy","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SN","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9554-9933","authenticated-orcid":false,"given":"Radhika","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-2099","authenticated-orcid":false,"given":"Jeewan S","family":"Titiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-7465","authenticated-orcid":false,"given":"Rasik","family":"Vajpayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"2025040105501747000_109.1.10.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30811-1"},{"key":"2025040105501747000_109.1.10.2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31802eb264"},{"key":"2025040105501747000_109.1.10.3","doi-asserted-by":"publisher","DOI":"10.1159\/000027505"},{"key":"2025040105501747000_109.1.10.4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2015.05.002","article-title":"Japanese research Committee on severe cutaneous adverse reaction. predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic Epidermal Necrolysis","volume":"160","author":"Sotozono","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2025040105501747000_109.1.10.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.66.8.536"},{"key":"2025040105501747000_109.1.10.6","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199915060-00004"},{"key":"2025040105501747000_109.1.10.7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1980.01020040625007"},{"key":"2025040105501747000_109.1.10.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003496","article-title":"The genome of Tolypocladium Inflatum: evolution, organization, and expression of the Cyclosporin Biosynthetic gene cluster","volume":"9","author":"Bushley","year":"2013","journal-title":"PLoS Genet"},{"key":"2025040105501747000_109.1.10.9","article-title":"Cyclosporin versus tacrolimus for liver transplanted patients","volume":"2006","author":"Haddad","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2025040105501747000_109.1.10.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(97)00930-7"},{"key":"2025040105501747000_109.1.10.11","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11681"},{"key":"2025040105501747000_109.1.10.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"2025040105501747000_109.1.10.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317907"},{"key":"2025040105501747000_109.1.10.14","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/416842","article-title":"Topical ophthalmic cyclosporine in the treatment of toxic Epidermal Necrolysis","volume":"2011","author":"Onaran","year":"2011","journal-title":"Case Rep Med"},{"key":"2025040105501747000_109.1.10.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.08.040"},{"key":"2025040105501747000_109.1.10.16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/09273948.2019.1587470","article-title":"Evaluation of the efficacy and safety of A novel 0.05% Cyclosporin A topical Nanoemulsion in primary Sj\u00f6gren\u2019s syndrome dry eye","volume":"28","author":"Kang","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"2025040105501747000_109.1.10.17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/OED.S16067","article-title":"Safety and efficacy of cyclosporine in the treatment of chronic dry eye","volume":"6","author":"Schultz","year":"2014","journal-title":"Ophthalmol Eye Dis"},{"key":"2025040105501747000_109.1.10.18","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41433-018-0037-z","article-title":"Topical Ciclosporin 1 mg\/ml for chronic ocular surface inflammation in children","volume":"32","author":"Parvizi","year":"2018","journal-title":"Eye (Lond)"},{"key":"2025040105501747000_109.1.10.19","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306930"},{"key":"2025040105501747000_109.1.10.20","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14831"},{"key":"2025040105501747000_109.1.10.21","first-page":"2195","article-title":"Ocular safety of Cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo Rabbit model","volume":"18","author":"Liang","year":"2012","journal-title":"Mol Vis"},{"key":"2025040105501747000_109.1.10.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jop.1996.12.1","article-title":"Stability of cyclosporine 1% in artificial tears","volume":"12","author":"Fiscella","year":"1996","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025040105501747000_109.1.10.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.10.029"},{"key":"2025040105501747000_109.1.10.24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S101627","article-title":"The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye","volume":"10","author":"Stonecipher","year":"2016","journal-title":"OPTH"},{"key":"2025040105501747000_109.1.10.25","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311801"},{"key":"2025040105501747000_109.1.10.26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2018.0106","article-title":"Ocular distribution of cyclosporine following topical administration of OTX-101 in New Zealand white rabbits","volume":"35","author":"Weiss","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025040105501747000_109.1.10.27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2018.09.063","article-title":"Use of cyclosporine for the treatment of Stevens-Johnson syndrome\/toxic Epidermal Necrolysis","volume":"85","author":"Shah","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025040105501747000_109.1.10.28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/ijdvl.IJDVL_201_16","article-title":"Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson syndrome\/toxic Epidermal Necrolysis: A record-based study","volume":"83","author":"Mohanty","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2025040105501747000_109.1.10.29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/idoj.IDOJ_326_20","article-title":"Cyclosporine in Stevens-Johnson syndrome and toxic Epidermal Necrolysis: experience from a tertiary care centre of South Rajasthan","volume":"12","author":"Balai","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"2025040105501747000_109.1.10.30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jtos.2020.05.003","article-title":"The effects of systemic cyclosporine in acute Stevens-Johnson syndrome\/toxic Epidermal Necrolysis on ocular disease","volume":"19","author":"Hall","year":"2021","journal-title":"Ocul Surf"},{"key":"2025040105501747000_109.1.10.31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/jop.2012.0009","article-title":"Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye","volume":"29","author":"Prabhasawat","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025040105501747000_109.1.10.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1388-8"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2023-324901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:04:46Z","timestamp":1743541486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2023-324901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bjo-2023-324901"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2023-324901","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}